• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
CYCC [ Cyclacel Pharmaceuticals Inc ]
Last Trade 5.76 Date 3/5/2021
Change % -5.58 % Price Change -0.34
Open 6.05 52 Week High 19.25
High 6.07 52 Week Low 3.12
Low 5.5401 Type stock
Volume 169410 Average Volume 262210
Prev Close 6.1 Stock Exchange NASDAQ
Bid 5.7 Ask 5.76
Bid Size 1 Ask Size 2
1st Yr Estimated EPS Growth -0.384 2nd Yr Estimated EPS Growth 0.1991
2 Years Forward Earning Yield -0.4148 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 4.682 Book Value Yield 0.7675
Buy Back Yield CAPE Ratio
Cash Return -0.7311 Cash Flow per Share -2.1836
Cash Flow Yield -0.358 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.5607 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset 0.2984
Expected Dividend Growth Rate Free Cash Flow per Share -2.2101
Free Caash Flow Ratio Free Cash Flow Yield -0.3623
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.3459 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.302873 PB Ratio 10 Year Growth -0.061128
PB Ratio 3 Year Growth 0.972964 Cash Ratio 3 Year Average 99.1132
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.884058
Price to Cash Ratio 1.29714 Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg 55.359294 Price to Sales Ratio 5 Year Avg
Sale per Share 0.0 Sales Yield 0.0
Sustainable Growth Rate -0.5526 Tangible Book Value per Share 4.682
Tangible Book Value per Share 3 year Avg 15.5271 Tangible Book Value per Share 5 year Avg 33.0562
Total Asset per Share 5.1807 Total Yield
Working Capital per Share 4.6431 Working Capital per Share 3 Year Avg 15.5181
Working Capital per Share 5 Year Avg 33.146 Beta 1.342713
Company Profile

Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancer and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with advanced solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.